Study of AK129 with or without AK117 for Hodgkin lymphoma after PD-1 treatment
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, AK129, alone or with another drug called AK117, for people with classic Hodgkin lymphoma that has not responded to or stopped responding to PD-1/L1 inhibitor therapy. The goal is to see if these combinations can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have classic Hodgkin lymphoma that returned or did not respond to previous treatment with a PD-1 or PD-L1 inhibitor.
- You are generally able to care for yourself (ECOG score 0 or 1).
- Your organs (like kidneys, liver, and bone marrow) are working well enough, as shown by blood tests.
- If you could become pregnant or father a child, you agree to use effective birth control during the study and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests AK129 in people with advanced cancers that have spread. It looks for a safe dose and early signs the treatment may work, especially for tumors with measurable disease and needed prior treatment options.
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
This trial tests a combination of two medicines—azacitidine and a PD-1 inhibitor—for people with Hodgkin lymphoma that has returned or not responded to previous treatment. The aim is to see if this combination can help control the disease.
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Hear when a new Classic Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.